46 / 58
Ruxolitinib
(JAK-1 and JAK-2 inhibitor)
407 pts
(J-1: 321 pts ; (J-2:+ 86 pts)
Metastatic Panc Cancer,
PCR hight
2nd line after Gem
Cape-Ruxolitinib
Cape- placebo
1º endpoint: OS
JANUS 1:
HR 0.96;
p 0.40
JANUS 2;
HR 1.58;
p 0.94
2º endpoint: PFS
JANUS 1:
HR 1.05;
p 0.66
JANUS 2;
HR 1.16;
p 0.72
P. III JANUS 1 and JANUS 2
Hurwitz H et al. ASCO-GI 2017